Literature DB >> 23192661

Novel galanin receptor subtype specific ligand in depression like behavior.

Indrek Saar1, Johan Runesson, Jaak Järv, Kaido Kurrikoff, Ulo Langel.   

Abstract

Neuropeptide galanin and its three receptors, galanin receptor type 1-galanin receptor type 3, are known to be involved in the regulation of numerous psychological processes, including depression. Studies have suggested that stimulation of galanin receptor type 2 (GalR2) leads to attenuation of the depression-like behavior in animals. However, due to the lack of highly selective galanin subtype specific ligands the involvement of different receptors in depression-like behavior is yet not fully known. In the present study we introduce a novel GalR2 selective agonist and demonstrate its ability to produce actions consistent with theorized GalR2 functions and analogous to that of the anti-depressant, imipramine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23192661     DOI: 10.1007/s11064-012-0933-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  22 in total

1.  Novel galanin receptor subtype specific ligands in feeding regulation.

Authors:  Indrek Saar; Johan Runesson; Ilan McNamara; Jaak Järv; John K Robinson; Ulo Langel
Journal:  Neurochem Int       Date:  2011-02-17       Impact factor: 3.921

2.  In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures.

Authors:  Andrey M Mazarati; Roger A Baldwin; Steve Shinmei; Raman Sankar
Journal:  J Neurochem       Date:  2005-10-07       Impact factor: 5.372

3.  Determining receptor-ligand interaction of human galanin receptor type 3.

Authors:  Johan Runesson; Ulla E Sollenberg; Wiktor Jurkowski; Samira Yazdi; Einar E Eriksson; Arne Elofsson; Ulo Langel
Journal:  Neurochem Int       Date:  2010-09-09       Impact factor: 3.921

4.  A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests.

Authors:  Alasdair M Barr; Jefferson W Kinney; Matthew N Hill; Xiaoying Lu; Shannon Biros; Julius Rebek; Tamas Bartfai
Journal:  Neurosci Lett       Date:  2006-07-18       Impact factor: 3.046

5.  Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors.

Authors:  H X Liu; P Brumovsky; R Schmidt; W Brown; K Payza; L Hodzic; C Pou; C Godbout; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

6.  A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus.

Authors:  Xiaoying Lu; Alasdair M Barr; Jefferson W Kinney; Pietro Sanna; Bruno Conti; M Margarita Behrens; Tamas Bartfai
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

7.  Mutagenesis study on human galanin receptor GalR1 reveals domains involved in ligand binding.

Authors:  K Kask; M Berthold; U Kahl; A Juréus; G Nordvall; U Langel; T Bartfai
Journal:  Ann N Y Acad Sci       Date:  1998-12-21       Impact factor: 5.691

Review 8.  The neuropeptide galanin as an in vivo modulator of brain 5-HT1A receptors: possible relevance for affective disorders.

Authors:  Sven Ove Ogren; Haleh Razani; Elin Elvander-Tottie; Jan Kehr
Journal:  Physiol Behav       Date:  2007-05-21

9.  A novel GalR2-specific peptide agonist.

Authors:  Johan Runesson; Indrek Saar; Linda Lundström; Jaak Järv; Ulo Langel
Journal:  Neuropeptides       Date:  2009-05-20       Impact factor: 3.286

Review 10.  Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine.

Authors:  K B Thor; M Kirby; L Viktrup
Journal:  Int J Clin Pract       Date:  2007-06-30       Impact factor: 2.503

View more
  5 in total

Review 1.  Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.

Authors:  Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

2.  Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray.

Authors:  Peng Wang; Hui Li; Swapnali Barde; Ming-Dong Zhang; Jing Sun; Tong Wang; Pan Zhang; Hanjiang Luo; Yongjun Wang; Yutao Yang; Chuanyue Wang; Per Svenningsson; Elvar Theodorsson; Tomas G M Hökfelt; Zhi-Qing David Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

Review 3.  Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.

Authors:  David Weinshenker; Philip V Holmes
Journal:  Brain Res       Date:  2015-11-20       Impact factor: 3.252

Review 4.  Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.

Authors:  Mervin Chávez-Castillo; Victoria Núñez; Manuel Nava; Ángel Ortega; Milagros Rojas; Valmore Bermúdez; Joselyn Rojas-Quintero
Journal:  Adv Pharmacol Sci       Date:  2019-01-03

5.  Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake.

Authors:  Anneke Kuipers; Márta Balaskó; Erika Pétervári; Andreas Koller; Susanne M Brunner; Gert N Moll; Barbara Kofler
Journal:  Neurotherapeutics       Date:  2021-12-02       Impact factor: 7.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.